Lexent Bio Email Format
Biotechnology ResearchCalifornia, United States0-1 Employees
Lexent Bio is a small biotechnology company based in San Francisco that focuses on liquid biopsy approaches for cancer diagnosis and treatment decisions. It is developing the Confera Dx assay to provide non-invasive cancer diagnostics and is exploring integration with sequencing platforms as part of its development path, aiming to fit into clinical laboratory workflows. The company operates within the precision oncology space, seeking to offer diagnostic tools that support oncological decision-making. The firm has pursued strategic collaborations to advance its portfolio, including a non-exclusive partnership with Illumina to develop an IVD kit for future NGS-based cancer diagnostics. In June 2020, Foundation Medicine, a Roche subsidiary, announced its acquisition of Lexent Bio to broaden its multiomic diagnostic capabilities. These developments position Lexent Bio within the broader oncology diagnostics ecosystem, with a footprint in the San Francisco area.